LAM-003, a new drug for treatment of tyrosine kinase inhibitor–resistant FLT3-ITD–positive AML

Author:

Beeharry Neil1ORCID,Landrette Sean1,Gayle Sophia1,Hernandez Marylens1,Grotzke Jeff E.1,Young Peter R.1,Beckett Paul1,Zhang Xuan2ORCID,Carter Bing Z.2,Andreeff Michael3ORCID,Halene Stephanie4,Xu Tian5,Rothberg Jonathan1,Lichenstein Henri1

Affiliation:

1. AI Therapeutics, Guilford, CT;

2. Department of Leukemia and

3. Department of Leukemia and Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX; and

4. Department of Hematology and

5. Howard Hughes Medical Institute, Department of Genetics, Yale School of Medicine, New Haven, CT

Abstract

Key Points The heat shock protein 90 inhibitor LAM-003 displays potent in vitro and in vivo activity as a single agent and combined with venetoclax. LAM-003 retains antileukemic activity against AML cells rendered resistant to FLT3 kinase inhibitors by mutation or stromal signaling.

Publisher

American Society of Hematology

Subject

Hematology

Cited by 14 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3